Excelsior Medical Co., Ltd. · TWSE:4104
Excelsior Medical — Investor Conference 2024/11/26
16 slides from Excelsior Medical's conference presentation, Nov 26, 2024
Slide 1: Excelsior Medical Co., Ltd. Investor Conference
Excelsior Medical Co., Ltd. Investor Conference 2024/11/26
Slide 2: Disclaimer
Disclaimer This presentation is prepared according to the audited or reviewed financial statements by CPA and the financial figures hereby are based on IFRS, please refer to the published financial statements for full content. The presentation may contain forward-looking information and may differ m
Slide 3: The Business Types
The Business Types Hemodialysis Aesthetic Medical Trading Business Medical Devices Medical Consumables Home Appliances Product Planning Sales Information Analysis Promotion Hemodialysis channel Pharma. Sales and Promotion Market Creative Aesthetic Medical channel Pharma. Distribution and Logistics M
Slide 4: Revenue Overview
Revenue Overview Excelsior yearly consolidated sales is more than NT $ 8.2 billion in 2023, the primary revenue comes from Excelsior (Hemodialysis), Dynamic (Aesthetic Medical), Arich (Pharmaceutical Logistics) and others. According to the company’s function, the business type can be characterized a
Slide 5: Operating Overview
Operating Overview Unit: NTD in thousands 5
Slide 6: Investment Overview
Investment Overview Unit: NTD in thousands 6
Slide 7: Profit after Tax Overview
Profit after Tax Overview Unit: NTD in thousands/ EPS: NTD in Dollars 7
Slide 8: Strategies and Outlook
Strategies and Outlook Long-Term Planning Continuing to follow the Mid-Term Planning government’s “The New Southbound Policy” and ⚫Externally, the Company will enter the production and seek strategic partners, continue manufacturing industry by to expand medical channels. investing in a HD solution
Slide 9: Balance Sheet
Balance Sheet Unit: In thousands NTD Current Assets: Cash and cash equivalents 2,506,995 2,614,786 5,935,972 Receivables 1,713,858 1,961,336 1,735,007 Other receivables Sioioric 3,853,342 3,602,074 Inventories 1,161,088 1,247,430 1,304,896 Other current assets 831,163 1,014,936 1,122,926 Total Curre
Slide 10: Balance Sheet (Liabilities and Equity)
ee Excelsior Healthcare Group, + Balance Sheet Unit: In thousands NTD Liabilities Current Liabilities Short- term borrowings 535,134 1,134,887 1,082,201 Payables 1,000,392 974,726 1,043,612 Other payables 3,215,075 3,464,888 7,109,694 Other current liabilities 1,001,444 1,104,256 973,922 Total Curre
Slide 11: Statement of Comprehensive Income
Statement of Comprehensive Income 11
Slide 12: Statements of Cash Flows
Statements of Cash Flows Unit: In thousands NTD—C—i‘(L—S (te | |S 963,700 1,144,080 859,581 JAdustments Cd (86,537) (164,775) (108,550) (108,221) (244,183) 231,334 (436,495) (642,241) 262,756 (312,958) (139,988) (135,800) 52,862 (26,530) 68,886 493,741 248,708 3,461,983 (109,311) (151,606) (222,304)
Slide 13: Statements of Cash Flows
Statements of Cash Flows Unit: In thousands NTD ee Cash Flows from Investing Activities Proceeds from disposal of financial assets at fair value through other comprehensive income Acquisition of financial assets at amortized cost (441,456) (658,219) (409,515) Proceeds from disposal of financial asse
Slide 14: Statements of Cash Flows
Statements of Cash Flows nit thousands DSCC) (494,021) (540,983) (691,344) (11,294) : - Proceeds from disposal of ownership interests in 47,736 159,043 | Others (183,742) (211,048) (263,616) Net Cash Flows used in Financing Activities (633,889) (104,512) (748,602) Effect of exchange rate changes on
Slide 15: Growing up with Long-term partners
Growing up with Long-term partners Excelsior has been operating for 30 years, accumulated core competitiveness with new ideas created, new models to integrate various professional medical fields. Excelsior will keep taking root in the Asia market, the business scope includes Taiwan, Hong Kong, China
Slide 16: Growing up with Long-term partners
Growing up with Long-term partners Excelsior has been operating for 30 years, accumulated core competitiveness with new ideas created, new models to integrate variously professional medical fields. Excelsior will keep take root in the Asia market, the business scope includes Taiwan, Hong Kong, China